TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00605397

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Imaging With Cu-64 Labeled Trastuzumab
Description: The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Imaging With Cu-64 Labeled Trastuzumab
Description: The remaining 20 patients will undergo one PET study.
Study: NCT04676607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7390
Description: SHR7390
Study: NCT04365907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zafatek tablets
Description: Once weekly new anti-diabetic drug approved only in Japan
Study: NCT05151796

Intervention type: DRUG
Intervention: Aspirin
Description: Daily aspirin intake for cardiovascular prevention
Study: NCT02615197

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical Behavior Therapy
Description: Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Prolonged Exposure protocol
Description: Includes an adapted version of Prolonged Exposure therapy for PTSD.
Study: NCT01552005

Intervention type: DRUG
Intervention: Saxagliptin
Description: No Intervention
Study: NCT02670980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent Retinal Implant System
Study: NCT04632563

Intervention type: OTHER
Intervention: Questionnaire including MSK-HQ (Musculoskeletal Health Questionnaire)
Description: A questionnaire regarding musculoskeletal past medical history and current symptoms.
Study: NCT01468974

Intervention type: DEVICE
Group type: OTHER
Intervention: ESPRIT BVS
Description: Subjects receiving ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries
Study: NCT00920868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 7.5 mg/kg IV day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 IV day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 850 mg/m2 PO BID on days 1-14
Study: NCT01735084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar13
Description: The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
Study: NCT00387335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study: NCT01255488

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to EBN-Search (without full-text manuscripts)
Description: Family nurse practitioner access to EBN-Search without availability of full-text manuscripts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to EBN-Search (without full-text manuscripts)
Description: Family nurse practitioner access to EBN-Search without availability of full-text manuscripts.
Study: NCT03903432

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: candidates for ESS will be referred to conventional CT scans of the sinuses. If surgery is to be performed, the patients will sign an informed consent and be referred for a sinus MRI.
Study: NCT02772133

Intervention type: PROCEDURE
Intervention: Primary PCI
Study: NCT01383720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve System
Description: The Lotus Valve System includes the Lotus Valve, a bovine tissue tri-leaflet bioprosthetic aortic valve, and the Lotus Delivery Catheter for guidance and placement.
Study: NCT01985243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and agriculture
Description: The intervention includes two components: (1) nutrition education on infant and young child nutrition, and (2) agriculture and small animal husbandry intervention to increase women's income and the accessibility of animal source foods for infants and young children.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iron-rich food & business literacy
Description: The intervention includes two components: (1) a behavioural change intervention to improve school meals and increase the available iron in adolescents' diets, (2) savings \& business literacy program for young female adolescents to encourage them to stay in school.
Study: NCT02521883

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sooma tDCS
Description: 2mA current applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: sham stimulation (current phased off after 20 secs) applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
Study: NCT00578045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
Study: NCT02129231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: calcined magnesia
Description: We ensured the patient took the drug at night before meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe/simvastatin
Description: We ensured the patient took the drug at night before meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: We ensured the patient took the drug at night before meals
Study: NCT02247778

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional plate osteosynthesis
Description: Standard incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mini-incision-type osteosynthesis
Description: Mini-incision
Study: NCT04488341

Intervention type: OTHER
Group type: OTHER
Intervention: aerobic exercises in addition to diet recommendations
Description: aerobic exercises time of session 40-50 min initial 10 min warm up exercises on treadmill in low intensity and active phase 20- 30 min intensity will increase until patient reach to target heart rate then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: diet recommendations
Description: control group will receive diet recommendations for 12 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: diet recommendations
Description: control group will receive diet recommendations for 12 weeks
Study: NCT01864993

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gluten
Description: The enrolled patients will be invited to follow a gluten free diet. Patients responsive to the diet will be invited to assume gluten or placebo following a double blind with cross over scheme

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gluten
Description: The enrolled patients will be invited to follow a gluten free diet. Patients responsive to the diet will be invited to assume gluten or placebo following a double blind with cross over scheme

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients responsive to the diet will be invited to blindly assume gluten or placebo following a double blind with cross over scheme

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients responsive to the diet will be invited to blindly assume gluten or placebo following a double blind with cross over scheme
Study: NCT02314026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suspected NASH BreathID test with 13C-Octanoate
Description: Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suspected NASH Breath test with 13C Methacetin
Description: Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water
Study: NCT01611727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin chemotherapy will be administered as a 75 mg/m2 intravenous (IV) infusion every 3 weeks, for six cycles. Dexamethasone (8mg) will be administered once daily for three days after chemotherapy. Ondansetron (Zofran™) will be used for anti-nausea prophylaxis.
Study: NCT04518241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI sessions
Description: Three counseling sessions lasting less than 60 minutes each to identify goals, factors that promote or impede goals, and increase readiness for ART with high adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI sessions
Description: Three counseling sessions lasting less than 60 minutes each to identify goals, factors that promote or impede goals, and increase readiness for ART with high adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI sessions
Description: Three counseling sessions lasting less than 60 minutes each to identify goals, factors that promote or impede goals, and increase readiness for ART with high adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI sessions
Description: Three counseling sessions lasting less than 60 minutes each to identify goals, factors that promote or impede goals, and increase readiness for ART with high adherence
Study: NCT01077284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching capsules
Study: NCT04518241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMQQ
Description: Weekly text messages with health information as well as motivational messages. Two days later a true/false quiz question is sent. Participants earn 4 points for answering correctly, 2 points for answering incorrectly, and 0 points for not answering. Participants earn $1 for each point. Messages are sent over 21 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMQQ
Description: Weekly text messages with health information as well as motivational messages. Two days later a true/false quiz question is sent. Participants earn 4 points for answering correctly, 2 points for answering incorrectly, and 0 points for not answering. Participants earn $1 for each point. Messages are sent over 21 weeks.
Study: NCT04552782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol CBM
Description: Trains approach or avoidance responses to alcohol cues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol CBM
Description: Trains approach or avoidance responses to alcohol cues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD CBM
Description: Trains approach or avoidance responses to trauma cues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD CBM
Description: Trains approach or avoidance responses to trauma cues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Sham
Description: Will not train approach or avoidance responses.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Alcohol Sham
Description: Will not train approach or avoidance responses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD Sham
Description: Will not train approach or avoidance responses.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: PTSD Sham
Description: Will not train approach or avoidance responses.
Study: NCT05517239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Oxaliplatin
Description: Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
Study: NCT03257982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BCI-FES hand therapy
Description: BCI-FES rehabilitation therapy of the upper limb
Study: NCT03811912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: CTP-543 administered as 8 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: CTP-543 administered as 8 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543 Matching Placebo
Description: Administered as tablets to aid treatment masking.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543 Matching Placebo
Description: Administered as tablets to aid treatment masking.
Study: NCT03737214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat
Description: Administered in hard gelatin capsules containing 250 mg of lucerastat.
Study: NCT01019655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin calcium
Description: nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
Study: NCT02833740

Intervention type: DEVICE
Group type: OTHER
Intervention: Click-MUAC prototype & regular MUAC tape
Description: Screening of children using Click-MUAC and regular MUAC tape
Study: NCT00670124

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero
Description: The patients are placed on a cooling mattress and body-core temperature is regulated to 33° C.
Study: NCT03108534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF1535 NEXThaler
Description: Rescue treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF1535 pMDI
Description: Rescue treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rescue treatment
Study: NCT03153332

Intervention type: OTHER
Intervention: surgical residents' comprehension of the hepatic anatomy
Description: Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.

Intervention type: OTHER
Intervention: surgical residents' comprehension of the hepatic anatomy
Description: Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.

Intervention type: OTHER
Intervention: surgical residents' comprehension of the hepatic anatomy
Description: Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.
Study: NCT02451748

Intervention type: OTHER
Group type: OTHER
Intervention: Lab Work
Description: Lab work to measure IL-7 and IL-7R

Intervention type: OTHER
Group type: OTHER
Intervention: Lab Work
Description: Lab work to measure IL-7 and IL-7R

Intervention type: DRUG
Group type: OTHER
Intervention: Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)
Description: Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection.

Intervention type: DRUG
Group type: OTHER
Intervention: Certolizumab pegol (CDP870, tradename Cimzia)
Description: rtolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine
Description: some patients are on 400mg/day of hydroxychloroquine.

Intervention type: DRUG
Group type: OTHER
Intervention: Sulfasalazine
Description: some patients are on 300 mg/day and some patients are on 1000 mg/day dose of sulfasalazine
Study: NCT00934778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Confocal microscopy and endocytoscopy
Description: 2 probe based imaging systems for use via the working channel of the bronchoscope. 0.5ml of methylene blue injected into airways for endocytoscopy. Each procedure takes about 2-3 minutes.
Study: NCT00317967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg pills daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 80 mg pills daily
Study: NCT00122031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation with Medtronic Activa Neurostimulator
Description: Deep brain stimulation (DBS) at 130 Hz
Study: NCT03405389

Intervention type: PROCEDURE
Intervention: MatrixWAVE MMF System
Description: Standard of care treatment of the injury and use of the MatrixWAVE MMF system to establish occlusion
Study: NCT03681275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 MG [Xeljanz]
Description: administered twice daily for two days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Tofacitinib
Description: administered twice daily for two days
Study: NCT02451748

Intervention type: DRUG
Group type: OTHER
Intervention: Medrol
Description: some patients are on 8mg/day of medrol

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: some patients are on 10mg /day, some patients are on 20 mg/day, some patients are on 2.5 mg/day, some patients are on 30 mg/day, and some patients are on 5 mg/day of prednisone

Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone
Description: some patients are on Triamcinolone 40-80mg IM monthly (received 40mg dose 1 week before blood draw, off enbrel 50mg weekly and SSZ 1000mg bid for \~ 3 months) some patients are on Triamcinolone 40mg IM monthly

Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen
Description: some patients are on 1000 mg/day of naproxen

Intervention type: DRUG
Group type: OTHER
Intervention: Leflunomide
Description: some patients are on 20mg/day of leflunomide

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate

Intervention type: DRUG
Group type: OTHER
Intervention: humira
Description: some patients are on Humira 40mg q2weeks
Study: NCT01706510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
Study: NCT01146938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimasartan
Description: single administration of fimasartan 120mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fimasartan
Description: single administration of fimasartan 120mg
Study: NCT02311595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reduced port laparoscopic distal gastrectomy
Study: NCT02278497

Intervention type: OTHER
Group type: OTHER
Intervention: ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR
Study: NCT02163629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management
Study: NCT02587000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal acetate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02897947

Intervention type: PROCEDURE
Intervention: Surgery for lumbar spinal stenosis in Norway

Intervention type: PROCEDURE
Intervention: Surgery for lumbar spinal stenosis in Sweden
Description: Surgery for neurogenic claudication due to lumbar spinal stenosis in Sweden

Intervention type: PROCEDURE
Intervention: Surgery for lumbar spinal stenosis in Denmark
Description: Surgery for neurogenic claudication due to lumbar spinal stenosis in Denmark
Study: NCT01984398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mg Androxal Formulation A
Description: Single dose of 12.5 mg Androxal formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mg Androxal Formulation B
Description: Single dose of 12.5 mg Androxal Formulation B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Androxal Formulation A
Description: Single dose of 25 mg Androxal formulation A